Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response.
Taxane and vinblastine represent two classes of microtubules-targeted agents for cancer chemotherapy. Although taxol and vinblastine are widely used for cancer treatment, resistance to these agents is frequently encountered in the clinic. An ongoing question has been what mechanisms are involved in the resistance of tumour cells to microtubules-targeted agents or how the clinical effectiveness can be improved. There is increasing evidence that microtubules interact with the endoplasmic reticulum (ER). Here, we have shown that taxol and vinblastine induce multiple arms of the ER stress response, including up-regulation of glucose-regulated protein 78 (GRP78) expression, X-box binding protein 1 splicing and eukaryotic initiation factor 2alpha phosphorylation. Abrogation of GRP78 induction sensitizes breast cancer cells to taxol and vinblastine. Treatment with (-)-epigallocatechin gallate (EGCG), a known GRP78 inhibitor, synergistically promotes taxol- and vinblastine-induced cell death. GRP78 knockdown or EGCG potentiates taxol- and vinblastine-induced activation of pro-apoptosis arms of the ER stress response, such as JNK phosphorylation, caspase-7 and PARP cleavage. Inhibition of JNK and caspase-7 abrogates EGCG sensitization of breast cancer cells to taxol and vinblastine. We conclude that induction of the unfolded protein response represents a novel mechanism underlying the efficacy and resistance to microtubules-targeted agents. Combination of compounds capable of suppressing GRP78 might be a novel approach for improving the effectiveness of microtubules-targeted chemotherapy.
Wang
Jiao
J
Division of Signal Transduction and Molecular Targeted Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yin
Yancun
Y
Hua
Hui
H
Li
Minjing
M
Luo
Ting
T
Xu
Li
L
Wang
Ranran
R
Liu
Dongbo
D
Zhang
You
Y
Jiang
Yangfu
Y
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D001943:Breast Neoplasms / Q000378:metabolism*; D053179:Caspase 7 / Q000378:metabolism; D002392:Catechin / Q000031:analogs & derivatives / Q000494:pharmacology; D045744:Cell Line, Tumor; D000091342:Endoplasmic Reticulum Chaperone BiP; D005260:Female; D006360:Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology*; D006801:Humans; D008870:Microtubules / Q000378:metabolism*; D017239:Paclitaxel / Q000494:pharmacology; D010766:Phosphorylation; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D056811:Unfolded Protein Response; D014747:Vinblastine / Q000494:pharmacology
D000970:Antineoplastic Agents; D000091342:Endoplasmic Reticulum Chaperone BiP; C000717247:HSPA5 protein, human; D006360:Heat-Shock Proteins; D014747:Vinblastine; D002392:Catechin; C045651:epigallocatechin gallate; D011065:Poly(ADP-ribose) Polymerases; D053179:Caspase 7; D017239:Paclitaxel
J Cell Biol. 1986 Oct;103(4):1557-68
3533956
Apoptosis. 2008 Dec;13(12):1505-12
18989785
J Cell Biol. 2002 Aug 5;158(3):487-96
12163471
Cancer Res. 2007 Apr 15;67(8):3734-40
17440086
Cancer Res. 2005 Jul 1;65(13):5785-91
15994954
Oncogene. 2003 Oct 20;22(47):7280-95
14576838
Cancer Res. 2007 Oct 15;67(20):9750-61
17942905
Cancer Res. 2004 Apr 1;64(7):2502-8
15059905
Biochemistry. 2006 Aug 8;45(31):9434-44
16878978
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20
15914550
Curr Biol. 2000 Jun 1;10(11):675-8
10837255
Nat Immunol. 2003 Apr;4(4):321-9
12612580
Cancer Cell. 2003 Jan;3(1):51-62
12559175
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19444-9
19033462
J Cell Biol. 2003 Jun 23;161(6):1021-8
12821640
Cancer Res. 2007 Jun 15;67(12):5880-8
17575157
Cancer Res. 2001 Jun 1;61(11):4450-8
11389075
J Biol Chem. 2003 Jun 6;278(23):20915-24
12665508
Cancer Res. 2007 Apr 15;67(8):3496-9
17440054
J Cell Mol Med. 2009 Nov-Dec;13(11-12):4540-50
19017364
Trends Cell Biol. 1995 Apr;5(4):143-8
14732139
Mol Cancer Res. 2008 Aug;6(8):1268-75
18708359
Nat Rev Cancer. 2004 Dec;4(12):966-77
15573118
Cell Cycle. 2006 May;5(9):1001-7
16639080
Cancer Res. 2008 Jan 15;68(2):498-505
18199545
Cancer Cell. 2007 Jun;11(6):498-512
17560332
Cancer Res. 2006 Sep 15;66(18):9260-9
16982771
Genome Biol. 2006;7(6):224
16938900
Cell Death Differ. 2008 Sep;15(9):1460-71
18551133
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1224-9
9037034
BMC Cancer. 2008 Dec 17;8:372
19087354
IUBMB Life. 2008 Jun;60(6):368-75
18384115
Mol Biol Cell. 1999 Apr;10(4):947-59
10198049
J Clin Invest. 1997 Sep 1;100(5):1282-93
9276747
Curr Mol Med. 2006 Feb;6(1):45-54
16472112
Science. 1995 Dec 8;270(5242):1595-601
7502068
Cell Motil Cytoskeleton. 1994;29(4):291-300
7859292
J Cell Biol. 2001 Jul 23;154(2):261-6
11470815
Nat Cell Biol. 2007 Dec;9(12):1381-91
18026091
Nature. 1995 Feb 16;373(6515):630-2
7854422
J Biol Chem. 2005 Mar 11;280(10):9439-49
15623521
Mutagenesis. 1998 Jul;13(4):321-35
9717168
Nature. 2005 May 26;435(7041):519-22
15917812
Cancer Res. 2007 Oct 15;67(20):9809-16
17942911
Biochim Biophys Acta. 2008 Apr;1785(2):96-132
18068131
J Cell Biol. 2001 Sep 3;154(5):925-36
11535616